These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 28715203)

  • 1. A Bioinorganic Approach to Fragment-Based Drug Discovery Targeting Metalloenzymes.
    Cohen SM
    Acc Chem Res; 2017 Aug; 50(8):2007-2016. PubMed ID: 28715203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MeLAD: an integrated resource for metalloenzyme-ligand associations.
    Li G; Su Y; Yan YH; Peng JY; Dai QQ; Ning XL; Zhu CL; Fu C; McDonough MA; Schofield CJ; Huang C; Li GB
    Bioinformatics; 2020 Feb; 36(3):904-909. PubMed ID: 31504189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Metal-Binding Isosteres of 8-Hydroxyquinoline as Metalloenzyme Inhibitor Scaffolds.
    Seo H; Jackl MK; Kalaj M; Cohen SM
    Inorg Chem; 2022 May; 61(19):7631-7641. PubMed ID: 35507007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Metalloenzymes by Boron-Containing Metal-Binding Pharmacophores.
    Xiao YC; Yu JL; Dai QQ; Li G; Li GB
    J Med Chem; 2021 Dec; 64(24):17706-17727. PubMed ID: 34875836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isosteres of hydroxypyridinethione as drug-like pharmacophores for metalloenzyme inhibition.
    Adamek RN; Credille CV; Dick BL; Cohen SM
    J Biol Inorg Chem; 2018 Oct; 23(7):1129-1138. PubMed ID: 30003339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metal-Binding Isosteres as New Scaffolds for Metalloenzyme Inhibitors.
    Dick BL; Cohen SM
    Inorg Chem; 2018 Aug; 57(15):9538-9543. PubMed ID: 30009599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective.
    Jiang Z; You Q; Zhang X
    Eur J Med Chem; 2019 Mar; 165():172-197. PubMed ID: 30684796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Metalloenzyme Inhibitors Based on Property Characterization: Strategy and Application for HDAC1 Inhibitors.
    Zhang L; Yang Y; Yang Y; Xiao Z
    Molecules; 2024 Feb; 29(5):. PubMed ID: 38474606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual screening against metalloenzymes for inhibitors and substrates.
    Irwin JJ; Raushel FM; Shoichet BK
    Biochemistry; 2005 Sep; 44(37):12316-28. PubMed ID: 16156645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MeDBA: the Metalloenzyme Data Bank and Analysis platform.
    Yu JL; Wu S; Zhou C; Dai QQ; Schofield CJ; Li GB
    Nucleic Acids Res; 2023 Jan; 51(D1):D593-D602. PubMed ID: 36243971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the hunt for metalloenzyme inhibitors: Investigating the presence of metal-coordinating compounds in screening libraries and chemical spaces.
    Schuck B; Brenk R
    Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300648. PubMed ID: 38279543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calorimetric studies of the interactions of metalloenzyme active site mimetics with zinc-binding inhibitors.
    Robinson SG; Burns PT; Miceli AM; Grice KA; Karver CE; Jin L
    Dalton Trans; 2016 Jul; 45(29):11817-29. PubMed ID: 27373714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
    Credille CV; Dick BL; Morrison CN; Stokes RW; Adamek RN; Wu NC; Wilson IA; Cohen SM
    J Med Chem; 2018 Nov; 61(22):10206-10217. PubMed ID: 30351002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting metalloenzymes: a strategy that works.
    White RJ; Margolis PS; Trias J; Yuan Z
    Curr Opin Pharmacol; 2003 Oct; 3(5):502-7. PubMed ID: 14559095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directed Evolution of Artificial Metalloenzymes: A Universal Means to Tune the Selectivity of Transition Metal Catalysts?
    Reetz MT
    Acc Chem Res; 2019 Feb; 52(2):336-344. PubMed ID: 30689339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The design of inhibitors for medicinally relevant metalloproteins.
    Jacobsen FE; Lewis JA; Cohen SM
    ChemMedChem; 2007 Feb; 2(2):152-71. PubMed ID: 17163561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metalloprotein and metallo-DNA/RNAzyme design: current approaches, success measures, and future challenges.
    Lu Y
    Inorg Chem; 2006 Dec; 45(25):9930-40. PubMed ID: 17140190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Metalloenzymes for Therapeutic Intervention.
    Chen AY; Adamek RN; Dick BL; Credille CV; Morrison CN; Cohen SM
    Chem Rev; 2019 Jan; 119(2):1323-1455. PubMed ID: 30192523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LmrR: A Privileged Scaffold for Artificial Metalloenzymes.
    Roelfes G
    Acc Chem Res; 2019 Mar; 52(3):545-556. PubMed ID: 30794372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting metalloproteins by fragment-based lead discovery.
    Johnson S; Barile E; Farina B; Purves A; Wei J; Chen LH; Shiryaev S; Zhang Z; Rodionova I; Agrawal A; Cohen SM; Osterman A; Strongin A; Pellecchia M
    Chem Biol Drug Des; 2011 Aug; 78(2):211-23. PubMed ID: 21564556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.